Biogen (BIIB)
(Delayed Data from NSDQ)
$200.59 USD
-3.46 (-1.70%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $200.60 +0.01 (0.00%) 5:14 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
BIIB 200.59 -3.46(-1.70%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
Other News for BIIB
IN BRIEF: Biogen's Leqembi approved to treat Alzheimer's in the UAE
Invesco Main Street Mid Cap Fund Q2 2024 Review
Invesco Main Street Fund Q2 2024 Review
Biogen Enhances Financial Flexibility with New Credit Facility
See How Biogen Ranks Among Analysts' Top Picks With Strong Buyback Activity